|
Synonyms: BPS 804 | BPS804
Compound class:
Antibody
Comment: BPS-804 is a fully human investigational monoclonal antibody targeting sclerostin (SOST), being developed by Mereo BioPharma and which is designed to improve bone density. BPS-804 is one of the clinical assets acquired from Novartis, in exchange for equity in Mereo BioPharma.
Development of anti-sclerostin antibodies by Novartis is claimed in patent WO2009047356 [2], although we cannot definitively conclude that BPS-804 is claimed within that patent application. The potential of sclerostin as a therapeutic target in bone diseases is reviewed by Lewiecki (2014) [3]. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
